BlackRock
ABCL icon

BlackRock’s AbCellera Biologics ABCL Stock Holding History

BlackRock’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.9M Sell
3,805,309
-234,927
-6% -$1.15M ﹤0.01% 3002
2026
Q1 		$14.1M Buy
4,040,236
+174,340
+5% +$627K ﹤0.01% 3285
2025
Q4 		$13.2M Buy
3,865,896
+224,117
+6% +$1M ﹤0.01% 3325
2025
Q3 		$18.3M Sell
3,641,779
-39,015
-1% -$172K ﹤0.01% 3139
2025
Q2 		$12.6M Buy
3,680,794
+104,586
+3% +$260K ﹤0.01% 3287
2025
Q1 		$7.97M Sell
3,576,208
-520,435
-13% -$1.49M ﹤0.01% 3431
2024
Q4 		$12M Buy
4,096,643
+107,951
+3% +$301K ﹤0.01% 3332
2024
Q3 		$10.4M Buy
3,988,692
+185,215
+5% +$513K ﹤0.01% 3389
2024
Q2 		$11.3M Sell
3,803,477
-97,087
-2% -$367K ﹤0.01% 3323
2024
Q1 		$17.7M Sell
3,900,564
-5,149
-0.1% -$26.3K ﹤0.01% 3060
2023
Q4 		$22.3M Buy
3,905,713
+496,267
+15% +$2.3M ﹤0.01% 2953
2023
Q3 		$15.7M Sell
3,409,446
-41,952
-1% -$255K ﹤0.01% 3078
2023
Q2 		$22.3M Sell
3,451,398
-10,242,897
-75% -$69.9M ﹤0.01% 2976
2023
Q1 		$103M Sell
13,694,295
-157,707
-1% -$1.43M ﹤0.01% 1996
2022
Q4 		$140M Buy
13,852,002
+1,282,862
+10% +$14.8M ﹤0.01% 1776
2022
Q3 		$124M Buy
12,569,140
+743,808
+6% +$8.16M ﹤0.01% 1819
2022
Q2 		$126M Buy
11,825,332
+9,378,033
+383% +$79.4M ﹤0.01% 1875
2022
Q1 		$23.9M Buy
2,447,299
+80,057
+3% +$758K ﹤0.01% 3061
2021
Q4 		$33.9M Buy
2,367,242
+1,390,655
+142% +$21.1M ﹤0.01% 2939
2021
Q3 		$19.6M Buy
976,587
+79,400
+9% +$1.4M ﹤0.01% 3291
2021
Q2 		$19.7M Buy
897,187
+41,714
+5% +$1.15M ﹤0.01% 3316
2021
Q1 		$29.1M Buy
855,473
+505,056
+144% +$20.1M ﹤0.01% 2970
2020
Q4 		$14.1M Buy
+350,417
New +$16M ﹤0.01% 3192

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock's ABCL Position: Q2 2026 in Review

BlackRock reduced its AbCellera Biologics (ABCL) stake by 5.8% in Q2 2026, selling an estimated $1.15M and leaving 3,805,309 shares worth $29.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3002.

BlackRock first reported a position in ABCL in Q4 2020 and has held it in 23 quarters since. The position peaked at $140M in Q4 2022. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • BlackRock held 3,805,309 shares of AbCellera Biologics worth $29.9M as of Q2 2026.
  • BlackRock sold 234,927 AbCellera Biologics shares in Q2 2026, an estimated $1.15M.
  • AbCellera Biologics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3002 holding.
  • BlackRock first reported a position in AbCellera Biologics in Q4 2020 and has held it in 23 quarters since.
  • BlackRock's AbCellera Biologics position peaked at $140M in Q4 2022.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.